Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial.
about
Relevant factors for the optimal duration of extended endocrine therapy in early breast cancer.Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer.Critical Role of Estrogen Receptor Alpha O-Glycosylation by N-Acetylgalactosaminyltransferase 6 (GALNT6) in Its Nuclear Localization in Breast Cancer Cells
P2860
Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Adjuvant tamoxifen and exemest ...... el, randomised, phase 3 trial.
@en
type
label
Adjuvant tamoxifen and exemest ...... el, randomised, phase 3 trial.
@en
prefLabel
Adjuvant tamoxifen and exemest ...... el, randomised, phase 3 trial.
@en
P2093
P50
P1433
P1476
Adjuvant tamoxifen and exemest ...... bel, randomised, phase 3 trial
@en
P2093
Annette Hasenburg
Caroline Seynaeve
Cornelis J H van de Velde
Daniel Rea
Elma Meershoek-Klein Kranenbarg
Erik J Blok
Gerrit-Jan Liefers
Jan B E Smeets
Johan W R Nortier
Luc Y Dirix
P304
P356
10.1016/S1470-2045(17)30419-9
P577
2017-07-18T00:00:00Z